Phenotypes associated with this allele

• Allele Symbol: Crbn^tm1.1Ble
• Allele Name: targeted mutation 1.1, Benjamin L Ebert
• Allele ID: MGI:6258757
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Crbn^tm1.1Ble/Crbn^tm1.1Ble	involves: C57BL/6	MGI:6280333
cn2	Crbn^tm1.1Ble/Crbn^tm1.1Ble Csnk1a1^tm1.1Ybn/Csnk1a1^+ Tg(Mx1-cre)1Cgn/?	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA	MGI:6280334

Genotype
MGI:6280333

hm1

• Allelic Composition: Crbn^tm1.1Ble/Crbn^tm1.1Ble
• Genetic Background: involves: C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

hematopoietic system

decreased common myeloid progenitor cell number ( J:267091 )

• administration of lenalidomide for 21 days results in a decrease in the proportion of multipotent progenitors, common myeloid progenitors and granulocyte-macrophage progenitors

• but not megakaryocyte-erythroid progenitors

abnormal bone marrow hematopoietic cell morphology ( J:267091 )

• following administration of lenalidomide, long and short term hematopoietic stem cells are decreased in the bone marrow

decreased granulocyte monocyte progenitor cell number ( J:267091 )

• administration of lenalidomide for 21 days results in a decrease in the proportion of multipotent progenitors, common myeloid progenitors and granulocyte-macrophage progenitors

• but not megakaryocyte-erythroid progenitors

thrombocytopenia ( J:267091 )

• administration of lenalidomide for 21 days results in a decrease in platelet counts

decreased leukocyte cell number ( J:267091 )

• administration of lenalidomide for 21 days results in a decrease in total white blood cell count as compared to controls

• however, red blood cell count is not affected

decreased granulocyte number ( J:267091 )

• administration of lenalidomide for 21 days results in a decrease in CD11b+ Gr1+ granuloctyes

decreased B cell number ( J:267091 )

• administration of lenalidomide for 21 days results in a decrease in the number of B220+ B cells

decreased T cell number ( J:267091 )

• administration of lenalidomide for 21 days results in a decrease in CD3+ T cells

homeostasis/metabolism

increased physiological sensitivity to xenobiotic ( J:267091 )

immune system

decreased leukocyte cell number ( J:267091 )

• administration of lenalidomide for 21 days results in a decrease in total white blood cell count as compared to controls

• however, red blood cell count is not affected

decreased granulocyte number ( J:267091 )

• administration of lenalidomide for 21 days results in a decrease in CD11b+ Gr1+ granuloctyes

decreased B cell number ( J:267091 )

• administration of lenalidomide for 21 days results in a decrease in the number of B220+ B cells

decreased T cell number ( J:267091 )

• administration of lenalidomide for 21 days results in a decrease in CD3+ T cells

mortality/aging

prenatal lethality, incomplete penetrance ( J:267091 )

• treatment with thalidomide or lenalidomide during pregnancy results in a high rate of fetal loss; there is no effect on wild-type mice

• fetal loss occurs by E10.5

• fetuses that survive to birth are smaller than controls, but otherwise have normal morphology

vision/eye

anophthalmia ( J:267091 )

• anophthalmia is observed in litters treated with thalidomide at E7.5

Genotype
MGI:6280334

cn2

• Allelic Composition: Crbn^tm1.1Ble/Crbn^tm1.1Ble; Csnk1a1^tm1.1Ybn/Csnk1a1⁺; Tg(Mx1-cre)1Cgn/?
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA

homeostasis/metabolism

increased physiological sensitivity to xenobiotic ( J:267091 )

• hematopoietic stem and progenitor cells are more sensitive to lenalidomide in culture than cells from Csnk1a1^tm1.1Ybn/+ Tg(Mx1-cre)1Cgn mice